These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 31599747)

  • 21. Novel pharmacological interventions for diabetic kidney disease.
    Tan SK; Pinzon-Cortes JA; Cooper ME
    Curr Opin Nephrol Hypertens; 2024 Jan; 33(1):13-25. PubMed ID: 37889557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mineralocorticoid Receptor Antagonists for Nephroprotection: Current Evidence and Future Perspectives.
    Sarafidis PA; Memmos E; Alexandrou ME; Papagianni A
    Curr Pharm Des; 2018; 24(46):5528-5536. PubMed ID: 30848187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C; Pöss J; Böhm M
    Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mineralocorticoid antagonists in chronic kidney disease.
    Dhaybi OA; Bakris G
    Curr Opin Nephrol Hypertens; 2017 Jan; 26(1):50-55. PubMed ID: 27753685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease.
    Kalantarinia K; Okusa MD
    Curr Diab Rep; 2006 Feb; 6(1):8-16. PubMed ID: 16522275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
    Schaefer JA; Gales MA
    Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists.
    Mende CW; Samarakoon R; Higgins PJ
    Am J Nephrol; 2023; 54(1-2):50-61. PubMed ID: 36682353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms.
    Epstein M; Kovesdy CP; Clase CM; Sood MM; Pecoits-Filho R
    Am J Kidney Dis; 2022 Nov; 80(5):658-666. PubMed ID: 36057467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mineralcorticoid receptor blockers in chronic kidney disease.
    Erraez S; López-Mesa M; Gómez-Fernández P
    Nefrologia (Engl Ed); 2021; 41(3):258-275. PubMed ID: 33358451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
    Tamargo J; Caballero R; Delpón E
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
    Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.
    Pichler RH; de Boer IH
    Curr Diab Rep; 2010 Aug; 10(4):297-305. PubMed ID: 20532701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
    Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR; Rolfe M
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aldosterone blockade in chronic kidney disease.
    Hirsch JS; Drexler Y; Bomback AS
    Semin Nephrol; 2014 May; 34(3):307-22. PubMed ID: 25016401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential RAAS blockade: is it worth the risk?
    Persson F; Rossing P
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):159-65. PubMed ID: 24602465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antifibrotic renal role of mineralcorticoid receptor antagonists].
    Ocello A; La Rosa S; Fiorini F; Randone S; Maccarrone R; Battaglia G; Granata A
    G Ital Nefrol; 2019 Jul; 36(4):. PubMed ID: 31373464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
    Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
    Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval.
    Zannad F; Rossignol P; Stough WG; Epstein M; Alonso Garcia Mde L; Bakris GL; Butler J; Kosiborod M; Berman L; Mebazaa A; Rasmussen HS; Ruilope LM; Stockbridge N; Thompson A; Wittes J; Pitt B
    Int J Cardiol; 2016 Aug; 216():46-51. PubMed ID: 27140336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes : Lessons from the FIGARO-DKD trial.
    Haller H
    Herz; 2022 Oct; 47(5):401-409. PubMed ID: 36094559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.